Find in Library

Neoadjuvant endocrine therapy (NET) instead of neoadjuvant chemotherapy (NCT) is an effective clinical strategy for estrogen receptor (ER)-positive breast cancer patients, which can reduce tumor stage, achieve breast-conserving surgery for breast cancer and reduce the need for adjuvant chemotherapy. This article aimed to review the latest research progress in several aeras: patient selection for NET, comparison of efficacy of NET, duration of NET, comparison and combined use of NET and NCT, NET combined with targeted therapy, window of opportunity trials, efficacy evaluation indicators and adjuvant therapy decision after neoadjuvant endocrine therapy.